Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

5.20USD
12 Oct 2018
Change (% chg)

-- (--)
Prev Close
$5.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
141,487
52-wk High
$11.16
52-wk Low
$5.02

Latest Key Developments (Source: Significant Developments)

Bellicum Pharma Files For Mixed Shelf Of Upto $150 Million
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Bellicum Pharmaceuticals Says On July 13, Co, CFO, Alan Musso Entered Separation Agreement After Which Musso Resigned Effective Aug 31
Monday, 16 Jul 2018 

July 16 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS SAYS ON JULY 13, CO, CFO, ALAN MUSSO ENTERED SEPARATION AGREEMENT AFTER WHICH MUSSO RESIGNED EFFECTIVE AUGUST 31 - SEC FILING.  Full Article

Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501.FDA CLINICAL HOLD DID NOT AFFECT BP-004 REGISTRATIONAL TRIAL IN EUROPE, WHICH IS FULLY ENROLLED.LIFT OF CLINICAL HOLD FOLLOWS CONSULTATION WITH FDA & AGREEMENT ON AMENDMENTS TO STUDY PROTOCOLS.BELLICUM WILL BE WORKING WITH U.S. CLINICAL SITES TO RESUME PATIENT RECRUITMENT BASED ON AMENDED PROTOCOLS.  Full Article

Bellicum reports qtrly earnings per share loss‍ $0.71​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum announces appointment of Rick Fair as CEO
Tuesday, 31 Jan 2017 

Bellicum Pharmaceuticals Inc : Bellicum announces appointment of Rick Fair as chief executive officer in preparation for commercialization of bpx-501 and next phase of growth . Bellicum pharmaceuticals - fair joins Bellicum from Genentech/Roche, where he was senior vice president, head of oncology global product strategy .Bellicum Pharmaceuticals Inc - Fair succeeds Tom Farrell, who will serve as an advisor to company during transition.  Full Article